Wikipedia:Choosing Wisely/American Psychiatric Association

Choosing Wisely is a health campaign which seeks to share health information with patients and health care providers.

This project shares information from the American Psychiatric Association on Wikipedia.

Articles of interest

Articles relating to American Psychiatric Association content
article	traffic in March 2014*	sources cited	change summary
American Psychiatric Association	7702
Antipsychotic	43385	1	antipsychotics should only be prescribed after a physician has conducted an initial evaluation and made a plan for appropriate ongoing monitoring
Antipsychotic	43385	2	Antipsychotics are prescribed one at a time
Dementia	91709	3	citation added; content already covered for geriatrics society
Insomnia	93657	4	The use of antipsychotics for insomnia, while common, is not recommended as the evidence does not demonstrate a benefit and the risk of adverse effects is significant.
Antipsychotic	43385	5	Antipsychotics should not be used in children or adolescents as a first-line treatment for anything other than a psychotic disorder.
Child and adolescent psychiatry	3616	5	antipsychotic drugs as a first-line treatment for mental health problems or behavioral issues other than a psychotic disorder, which is contrary to the intended use of the drugs

• *An arbitrary month has been chosen to present a count of pageviews. This month is neither the busiest nor slowest month, and this number seems typical for most articles in most months. Through the link anyone may check traffic in other months.

Recent changes

Review changes to all of the articles in the above table by visiting this watchlist.

References

American Psychiatric Association (September 2013), "Five Things Physicians and Patients Should Question", Choosing Wisely: an initiative of the ABIM Foundation, American Psychiatric Association, retrieved 30 December 2013, which cites

1. • Association, American Psychiatric (2006). "Psychiatric Evaluation of Adults, Second Edition". APA Practice Guidelines for the Treatment of Psychiatric Disorders: Comprehensive Guidelines and Guideline Watches. Vol. 1. doi:10.1176/appi.books.9780890423363.137162. ISBN 978-0-89042-336-3.
   • American Diabetes, A.; American Psychiatric, A.; American Association of Clinical Endocrinologists; North American Association for the Study of Obesity (2004). "Consensus Development Conference on Antipsychotic Drugs and Obesity and Diabetes". Diabetes Care. 27 (2): 596–601. doi:10.2337/diacare.27.2.596. PMID 14747245.
   • Lisa Dixon; Diana Perkins; Christine Calmes (September 2009). Guideline Watch (September 2009): Practice Guideline for the Treatment of Patients With Schizophrenia. doi:10.1176/appi.books.9780890423929.501001. ISBN 9780890423929.
   • Maglione, M.; Maher, A. R.; Hu, J.; Wang, Z.; Shanman, R.; Shekelle, P. G.; Roth, B.; Hilton, L.; Suttorp, M. J.; Ewing, B. A.; Motala, A.; Perry, T. (2011). "Off-Label Use of Atypical Antipsychotics: An Update". PMID 22132426. {{cite journal}}: Cite journal requires |journal= (help)
   • Nasrallah, H. A. (2007). "Atypical antipsychotic-induced metabolic side effects: Insights from receptor-binding profiles". Molecular Psychiatry. 13 (1): 27–35. doi:10.1038/sj.mp.4002066. PMID 17848919.
2. • Association, American Psychiatric (2006). "Practice Guideline for the Treatment of Patients With Schizophrenia Second Edition". APA Practice Guidelines for the Treatment of Psychiatric Disorders: Comprehensive Guidelines and Guideline Watches. Vol. 1. doi:10.1176/appi.books.9780890423363.45859. ISBN 978-0-89042-336-3.
   • Kane, J.; Honigfeld, G.; Singer, J.; Meltzer, H. (1988). "Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine". Archives of General Psychiatry. 45 (9): 789–796. doi:10.1001/archpsyc.1988.01800330013001. PMID 3046553.
   • McEvoy, J.; Lieberman, J. A.; Stroup, T. S.; Davis, S. M.; Meltzer, H. Y.; Rosenheck, R. A.; Swartz, M. S.; Perkins, D. O.; Keefe, R. S.; Davis, C. E.; Severe, J.; Hsiao, J. K.; Catie, I. (2006). "Effectiveness of Clozapine Versus Olanzapine, Quetiapine, and Risperidone in Patients with Chronic Schizophrenia Who Did Not Respond to Prior Atypical Antipsychotic Treatment". American Journal of Psychiatry. 163 (4): 600–610. doi:10.1176/appi.ajp.163.4.600. PMID 16585434.
   • Maglione, M.; Maher, A. R.; Hu, J.; Wang, Z.; Shanman, R.; Shekelle, P. G.; Roth, B.; Hilton, L.; Suttorp, M. J.; Ewing, B. A.; Motala, A.; Perry, T. (2011). "Off-Label Use of Atypical Antipsychotics: An Update". PMID 22132426. {{cite journal}}: Cite journal requires |journal= (help)
   • Joint Commission (30 June 2013), "HBIPS-4, Patients discharged on multiple antipsychotic medications", Specifications Manual for Joint Commission National Quality Core Measures, retrieved 27 October 2013
   • Stahl, S. M.; Grady, M. M. (2004). "A critical review of atypical antipsychotic utilization: Comparing monotherapy with polypharmacy and augmentation". Current Medicinal Chemistry. 11 (3): 313–327. doi:10.2174/0929867043456070. PMID 14965234.
3. • Association, American Psychiatric (2006). "Practice Guideline for the Treatment of Patients With Alzheimer's Disease and Other Dementias, Second Edition". APA Practice Guidelines for the Treatment of Psychiatric Disorders: Comprehensive Guidelines and Guideline Watches. Vol. 1. doi:10.1176/appi.books.9780890423967.152139. ISBN 978-0-89042-336-3.
   • Ballard, C. G.; Waite, J.; Birks, J. (2006). Ballard, Clive G (ed.). "Atypical antipsychotics for aggression and psychosis in Alzheimer's disease". The Cochrane Library (1): CD003476. doi:10.1002/14651858.CD003476.pub2. PMID 16437455.
   • Gitlin, L. N.; Kales, H. C.; Lyketsos, C. G. (2012). "Nonpharmacologic Management of Behavioral Symptoms in Dementia". JAMA. 308 (19): 2020–2029. doi:10.1001/jama.2012.36918. PMC 3711645. PMID 23168825.
   • Maglione, M.; Maher, A. R.; Hu, J.; Wang, Z.; Shanman, R.; Shekelle, P. G.; Roth, B.; Hilton, L.; Suttorp, M. J.; Ewing, B. A.; Motala, A.; Perry, T. (2011). "Off-Label Use of Atypical Antipsychotics: An Update". PMID 22132426. {{cite journal}}: Cite journal requires |journal= (help)
   • Nasrallah, H. A. (2007). "Atypical antipsychotic-induced metabolic side effects: Insights from receptor-binding profiles". Molecular Psychiatry. 13 (1): 27–35. doi:10.1038/sj.mp.4002066. PMID 17848919.
   • Richter, T.; Meyer, G.; Möhler, R.; Köpke, S. (2012). Köpke, Sascha (ed.). "Psychosocial interventions for reducing antipsychotic medication in care home residents". The Cochrane Library. 12: CD008634. doi:10.1002/14651858.CD008634.pub2. PMC 6492452. PMID 23235663.
   • Schneider, L. S.; Tariot, P. N.; Dagerman, K. S.; Davis, S. M.; Hsiao, J. K.; Ismail, M. S.; Lebowitz, B. D.; Lyketsos, C. G.; Ryan, J. M.; Stroup, T. S.; Sultzer, D. L.; Weintraub, D.; Lieberman, J. A.; Catie-Ad Study, G. (2006). "Effectiveness of Atypical Antipsychotic Drugs in Patients with Alzheimer's Disease". New England Journal of Medicine. 355 (15): 1525–1538. doi:10.1056/NEJMoa061240. PMID 17035647.
4. • American Diabetes, A.; American Psychiatric, A.; American Association of Clinical Endocrinologists; North American Association for the Study of Obesity (2004). "Consensus Development Conference on Antipsychotic Drugs and Obesity and Diabetes". Diabetes Care. 27 (2): 596–601. doi:10.2337/diacare.27.2.596. PMID 14747245.
   • Maglione, M.; Maher, A. R.; Hu, J.; Wang, Z.; Shanman, R.; Shekelle, P. G.; Roth, B.; Hilton, L.; Suttorp, M. J.; Ewing, B. A.; Motala, A.; Perry, T. (2011). "Off-Label Use of Atypical Antipsychotics: An Update". PMID 22132426. {{cite journal}}: Cite journal requires |journal= (help)
   • Nasrallah, H. A. (2007). "Atypical antipsychotic-induced metabolic side effects: Insights from receptor-binding profiles". Molecular Psychiatry. 13 (1): 27–35. doi:10.1038/sj.mp.4002066. PMID 17848919.
5. • Correll, C. U. (2008). "Monitoring and management of antipsychotic-related metabolic and endocrine adverse events in pediatric patients". International Review of Psychiatry. 20 (2): 195–201. doi:10.1080/09540260801889179. PMID 18386212.
   • McClellan, J.; Kowatch, R.; Findling, R. L.; Work Group on Quality Issues (2007). "Practice Parameter for the Assessment and Treatment of Children and Adolescents with Bipolar Disorder". Journal of the American Academy of Child & Adolescent Psychiatry. 46 (1): 107–125. doi:10.1097/01.chi.0000242240.69678.c4. PMID 17195735.
   • Loy, J. H.; Merry, S. N.; Hetrick, S. E.; Stasiak, K. (2012). Loy, Jik H (ed.). "Atypical antipsychotics for disruptive behaviour disorders in children and youths". The Cochrane Library. 9 (9): CD008559. doi:10.1002/14651858.CD008559.pub2. PMID 22972123.
   • Zito, J. M.; Burcu, M.; Ibe, A.; Safer, D. J.; Magder, L. S. (2013). "Antipsychotic Use by Medicaid-Insured Youths: Impact of Eligibility and Psychiatric Diagnosis Across a Decade". Psychiatric Services. 64 (3): 223–229. doi:10.1176/appi.ps.201200081. PMID 23242390.

Links

• American Psychiatric Association